Physician profile
Scott Howell
NPI 1215912753
$1,791.88
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $700 · 2021: $326 · 2022: $16.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $326.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $301.92 | 2019-2020 | |
| Novo Nordisk INC | $188.42 | 2019-2021 | |
| Lilly USA, LLC | $141.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $135.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $119.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $94.48 | 2019-2020 | |
| Abbott Laboratories | $88.65 | 2021 | |
| Intuitive Surgical, INC. | $83.74 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $74.54 | 2019-2020 | |
| Amarin Pharma, INC. | $52.72 | 2019-2020 | |
| Esperion Therapeutics, INC. | $48.31 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $41.28 | 2019-2020 | |
| Amgen INC. | $27.28 | 2019 | |
| Boston Scientific Corporation | $24.60 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $16.36 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2021 | |
| Glaxosmithkline, LLC. | $13.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.